nach oben

Erschienen in:

15.04.2021 | Brief Communication

Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series

verfasst von: Russo Cinzia Valeria, Lanzillo Roberta, Saccà Francesco, Moccia Marcello, Carotenuto Antonio, Brescia Morra Vincenzo

Erschienen in: Neurological Sciences | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.

European Medicine Agency Lemtrada: summary of product characteristics. 2017

Abramsky O (1994) Pregnancy and multiple sclerosis. Ann Neurol 36(Suppl):S38–S41. https://doi.org/10.1002/ana.410360712CrossRefPubMed

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL, Care MS II, Investigators C (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89(11):1117–1126. https://doi.org/10.1212/WNL.0000000000004354CrossRefPubMedPubMedCentral

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3CrossRefPubMed

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78(14):1069–1078. https://doi.org/10.1212/WNL.0b013e31824e8ee7CrossRefPubMed

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839. https://doi.org/10.1016/S0140-6736(12)61768-1CrossRefPubMed

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ, Care-Ms I, Investigators C (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89(11):1107–1116. https://doi.org/10.1212/WNL.0000000000004313CrossRefPubMedPubMedCentral

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pasto L, Giannini M, Trojano M, Comi G, Amato MP, Society MSSGotIN (2018) Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks. Neurology 90(10):e823–e831. https://doi.org/10.1212/WNL.0000000000005067CrossRefPubMed

Rog D, Oh J, Chambers C, Hellwig K, McCombe P, Otero S, Margolin DH, Daizadeh N, Compston DAS (2017) Pregnancy Outcomes in patients with RRMS treated with Alemtuzumab from the clinical development program. Paper presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25–28 October 2017

10.

Leruez-Ville M, Foulon I, Pass R, Ville Y (2020) Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2020.02.018

Titel: Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series
verfasst von: Russo Cinzia Valeria
Lanzillo Roberta
Saccà Francesco
Moccia Marcello
Carotenuto Antonio
Brescia Morra Vincenzo
Publikationsdatum: 15.04.2021
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 8/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04975-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Symptoms of gait and coordination impairment in a patient with COVID-19 interstitial pneumonia

Psychometric features of Neuropathic Pain Symptom Inventory in Iranian people with Parkinson’s disease

Impact of COVID-19 on chronic migraine treated with erenumab: a case report

Multicentre, clinical trial of burst spinal cord stimulation for neck and upper limb pain NU-BURST: a trial protocol

Regular physical activity postpones age of occurrence of first-ever stroke and improves long-term outcomes

Impact of dietary polyphenols on neuroinflammation-associated disorders

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie